HealthCare Global Enterprises Limited has announced its financial results for the quarter and year ended March 31, 2026. The company reported a robust 15% annual revenue growth to Rs. 25,454 million. Adjusted EBITDA surged by 19% to Rs. 4,711 million for the full year, while the fourth quarter saw a notable 363% increase in adjusted profit after tax compared to the same period last year.
Annual Financial Performance
For the financial year ended March 31, 2026, HealthCare Global Enterprises reported a strong performance across its network. Annual revenue from operations reached Rs. 25,454 million, representing a 15% increase over the previous year. The company’s focus on disciplined cost management and capacity utilization resulted in an adjusted EBITDA of Rs. 4,711 million, marking a growth of 19% with margins improving to 18.5%.
Fourth Quarter Highlights
The momentum continued into the final quarter (January-March 2026), with revenues growing by 11% to Rs. 6,523 million. Adjusted EBITDA for the quarter rose by 17% to Rs. 1,252 million, with margins expanding to 19.2%. Notably, the adjusted profit after tax for Q4 FY26 reached Rs. 341 million, a significant increase from Rs. 74 million reported in the same quarter of the previous year.
Strategic Milestones and Future Focus
Management highlighted the successful completion of a Rs. 4,250 million rights issue during the year, which has bolstered the company’s financial foundation. This capital is earmarked for long-term priorities, including capacity expansion, infrastructure upgrades, and technology investments in oncology. The company continues to prioritize its integrated care model, leveraging tumour-board-led clinical decision-making to maintain its position as a leading cancer care provider in India and Africa.
Leadership Perspective
Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, emphasized the shift toward precision medicine, molecular diagnostics, and robotics as key growth drivers. CEO Dr. Manish Mattoo credited the strong full-year performance to consistent execution across regional clusters and resilient demand across medical, radiation, and surgical oncology modalities.
Source: BSE
